Nisfevitug Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Targeting the spike protein of severe acute respiratory syndrome coronavirus 2 underpins much antiviral and neutralization research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of nisfevitug, made in CHO cells against SARS-CoV-2. Supplied strictly for research use only, it is formulated to low endotoxin for in vivo suitability and produced in scalable milligram (mg) to gram (g) quantities to meet the demands of high-throughput laboratories. It serves as a defined comparator and active reagent in functional assays, neutralization screens, epitope mapping, and preclinical coronavirus studies. Uniform quality across lots underpins confident comparisons in long-running projects.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks